UBS Maintains Buy on Neurocrine Biosciences, Raises Price Target to $193
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Ashwani Verma maintains a Buy rating on Neurocrine Biosciences (NASDAQ:NBIX) and raises the price target from $174 to $193.
May 28, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst Ashwani Verma maintains a Buy rating on Neurocrine Biosciences and raises the price target from $174 to $193, indicating confidence in the company's future performance.
The raised price target and maintained Buy rating from a reputable analyst at UBS suggest positive sentiment and confidence in Neurocrine Biosciences' future performance, likely leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100